Inhibitory killer cell immunoglobulin-like receptors strengthen CD8+ T cell–mediated control of HIV-1, HCV, and HTLV-1

See allHide authors and affiliations

Science Immunology  09 Nov 2018:
Vol. 3, Issue 29, eaao2892
DOI: 10.1126/sciimmunol.aao2892

Article Information

vol. 3 no. 29

Published By: 
  • Received July 4, 2017
  • Revision received June 6, 2018
  • Accepted October 9, 2018
Other Contributors: 
  • IAVI Protocol C Investigators

Author Information

  1. Lies Boelen1,
  2. Bisrat Debebe1,
  3. Marcos Silveira1,2,
  4. Arafa Salam3,
  5. Julia Makinde4,
  6. Chrissy h. Roberts5,
  7. Eddie C. Y. Wang6,
  8. John Frater7,8,
  9. Jill Gilmour4,
  10. Katie Twigger1,
  11. Kristin Ladell6,
  12. Kelly L. Miners6,
  13. Jyothi Jayaraman9,
  14. James A. Traherne9,
  15. David A. Price6,
  16. Ying Qi10,
  17. Maureen P. Martin10,
  18. Derek C. Macallan3,
  19. IAVI Protocol C Investigators*,
  20. Chloe L. Thio11,
  21. Jacquie Astemborski11,
  22. Gregory Kirk11,
  23. Sharyne M. Donfield12,
  24. Susan Buchbinder13,
  25. Salim I. Khakoo14,
  26. James J. Goedert15,
  27. John Trowsdale9,
  28. Mary Carrington10,16,
  29. Simon Kollnberger6 and
  30. Becca Asquith1,
  1. 1Department of Medicine, Imperial College London, London, UK.
  2. 2Faculty of Engineering, São Paulo State University—UNESP, São Paulo, Brazil.
  3. 3Institute for Infection and Immunity, St. George’s, University of London, London, UK.
  4. 4International AIDS Vaccine Initiative Human Immunology Laboratory, London, UK.
  5. 5Clinical Research Department, London School of Hygiene and Tropical Medicine, London, UK.
  6. 6Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
  7. 7Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  8. 8Oxford NIHR Biomedical Research Centre, Oxford, UK.
  9. 9Immunology Division, Department of Pathology, University of Cambridge, Cambridge, UK.
  10. 10Cancer and Inflammation Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  11. 11Johns Hopkins University, Baltimore, MD, USA.
  12. 12Rho, Chapel Hill, NC, USA.
  13. 13San Francisco Department of Public Health, San Francisco, CA, USA.
  14. 14Faculty of Medicine, University of Southampton, Southampton, UK.
  15. 15Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  16. 16Ragon Institute of MGH, MIT and Harvard, Boston, MA, USA.
  1. Corresponding author. Email: b.asquith{at}
  • * IAVI Protocol C Investigators are listed in the Supplementary Materials.


Article usage

Article usage: November 2018 to May 2019

Nov 201811487922946
Dec 2018116419273
Jan 201930911751
Feb 20191484017
Mar 20191514730
Apr 201986178
May 201998106